

# The effect of allopurinol on carotid ultrasound intima-media thickness and markers of endothelial function in patients with recent stroke - a pilot study

<b>Submission date</b> 19/09/2008	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 16/01/2009	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
<b>Last Edited</b> 27/06/2014	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr Matthew Walters

### Contact details

Department of Medicine and Cardiovascular Sciences

Western Infirmary

Dumbarton Road

Glasgow

United Kingdom

G11 6NT

+44 (0)141 2112821

m.walters@clinmed.gla.ac.uk

## Additional identifiers

### Protocol serial number

TSA IMT 01

## Study information

**Scientific Title**

The effect of allopurinol on carotid ultrasound intima-media thickness and markers of endothelial function in patients with recent stroke: a double-blind randomised placebo-controlled pilot trial

**Study objectives**

That allopurinol 300 mg per day will reduce rate of carotid intima-media thickness progression.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

West Medical Ethics Committee, approved on 19/08/2008.

**Study design**

Randomised double-blind placebo-controlled trial

**Primary study design**

Interventional

**Study type(s)**

Prevention

**Health condition(s) or problem(s) studied**

Cerebral infarction and transient ischaemic attack

**Interventions**

One year course of allopurinol (oral) 300 mg per day or placebo.

Details of Joint Sponsor:

University of Glasgow

University Avenue

Glasgow G12 8QQ

United Kingdom

**Intervention Type**

Drug

**Phase**

Phase IV

**Drug/device/biological/vaccine name(s)**

Allopurinol

**Primary outcome(s)**

Change in carotid intima-media thickness over a one year period (intima-media thickness [IMT] progression rate).

**Key secondary outcome(s)**

The following will be assessed at baseline, 6 and 12 months:

1. Levels of endothelial progenitor cells (EPCs) and circulating markers of endothelial function
2. Number of adverse events

**Completion date**

01/11/2011

## **Eligibility**

**Key inclusion criteria**

1. Both males and females, aged over 18
2. Ischaemic Stroke (including transient ischaemic attack [TIA] where symptoms last less than 24 hours)
3. Brain imaging not suggestive of an alternative diagnosis
4. Randomisation within one year of ictus

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Key exclusion criteria**

1. >70% extra-cranial internal carotid artery stenosis
2. Significant co-morbidity or frailty likely to cause death within 12 months or likely to make adherence to study protocol difficult for participant
3. Contra-indication to or indication for administration of allopurinol
4. Concurrent azathioprine or 6-mercaptopurine therapy
5. Significant hepatic impairment (defined as serum bilirubin, aspartate aminotransferase [AST] or alanine aminotransferase [ALT] greater than three times upper limit of normal [ULN])
6. Estimated glomerular filtration rate <50 mls/min
7. Cognitive impairment deemed sufficient to compromise capacity to consent or to comply with the protocol
8. Women of childbearing potential
9. Prisoners

**Date of first enrolment**

01/11/2008

**Date of final enrolment**

01/11/2011

## Locations

### Countries of recruitment

United Kingdom

Scotland

### Study participating centre

Department of Medicine and Cardiovascular Sciences

Glasgow

United Kingdom

G11 6NT

## Sponsor information

### Organisation

NHS Greater Glasgow and Clyde (UK)

### ROR

<https://ror.org/05kdz4d87>

## Funder(s)

### Funder type

Charity

### Funder Name

The Stroke Association (UK) (ref: TSA 2007/10)

## Results and Publications

### Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/07/2014		Yes	No